Prostate Cancer News

Minimally Invasive Prostate Surgery May Have Pros and Cons (October 14, 2009)

Laparoscopic radical prostatectomy, a less invasive surgical procedure that has gained in popularity in recent years, appears to result in shorter hospital stays, fewer blood transfusions, and fewer postoperative respiratory complications than open, retropubic... Continue Reading

Addition of Androgen Deprivation Therapy Improves Survival with Locally Advanced Prostate Cancer (October 8, 2009)

In men with locally advanced prostate cancer, the addition of androgen deprivation therapy to radiation therapy improves overall and progression-free survival without substantially affecting cardiovascular mortality. These results, based on close to 10... Continue Reading

Hormone Therapy in Prostate Cancer Increases Risk of Heart Disease (October 6, 2009)

Hormone therapy used to treat men with advanced prostate cancer may lead to an increased risk of heart disease, according to the results of a study presented on September 22, 2009 at Europe’s largest cancer congress, ECCO 15-ESMO 34, in Berlin.[1] Prostate... Continue Reading

Obese Men Have Higher-grade and Larger Prostate Cancers (September 21, 2009)

Obese men with prostate cancer have higher-grade, larger tumors, according to a study published in Prostate Cancer and Prostatic Diseases.[1] Body mass index (BMI) is a measurement of height and weight utilized to indicate body fat. A BMI between 18.5... Continue Reading

Watchful Waiting Appropriate for Some Men with Prostate Cancer (September 8, 2009)

Survival among men who choose to delay prostate cancer treatment appears to be similar to survival among men who choose immediate treatment. These results were published in the Journal of Clinical Oncology. Men with early-stage prostate cancer have the... Continue Reading

Androgen-deprivation Therapy Increases Risk of Death in Men with Heart Disease (September 1, 2009)

Among men with prostate cancer and a history of heart attack or congestive heart failure, receipt of androgen-deprivation therapy prior to radiation therapy increased the risk of death. These results were published in the Journal of the American Medical... Continue Reading

Clodronate Improves Survival in Metastatic Prostate Cancer (August 25, 2009)

Clodronate reduces the risk of death by 23% in men with metastatic prostate cancer, according to the results of a study published in The Lancet Oncology.[1] Clodronate belongs to a class of drugs called bisphosphonates. Bisphosphonates are agents used... Continue Reading

Denosumab Reduces Fractures in Non-metastatic Prostate Cancer (August 11, 2009)

Men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer experienced a 62% reduction in risk of vertebral fractures when treated with denosumab compared to men treated with placebo, according to the results of a study published... Continue Reading

Denosumab Shows Bone Benefits in Two Pivotal Studies (August 11, 2009)

Denosumab increases bone mineral density (BMD) and reduces the risk of vertebral fractures in women with postmenopausal osteoporosis as well as men treated with androgen deprivation therapy for non-metastatic prostate cancer, according to the results... Continue Reading

“Watchful Waiting” in Prostate Cancer Does Not Increase Anxiety (August 4, 2009)

Men who choose to delay treatment for early prostate cancer do not experience increased anxiety from living with the disease, according to the results of a study published in Cancer.[1] Prostate cancer is typically a disease of aging. It may persist undetected... Continue Reading